MedTrace Logo

Coagulation System In STereotactic Radiotherapy Of NSCLC

NCT03893461 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2021-07-22

No results posted yet for this study

Summary

The risk of thromboembolism is elevated in lung cancer patients. The present project investigates whether stereotactic body radiation therapy (SBRT) further increases the risk of thromboembolic disease in lung cancer patients.

If coagulation is activated by SBRT, this study could form the basis of new clinical trials investigating whether lung cancer patients may benefit from thromboprophylaxis during and after stereotactic body radiation therapy.

Conditions

Interventions

RADIATION

x

Stereotactic body radiation therapy for localized NSCLC

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Stefan S Jeppesen, MD, PhD · Department of Oncology, Odense University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2021-06-30
Completion
2022-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03893461 on ClinicalTrials.gov